文献速递淋巴瘤造血干细胞移植与细胞治疗

Tisagenlecleucel在复发/难治性DLBCL中的细胞动力学、剂量与免疫原性及其与临床因素的关系

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
PubMed 文献 · Blood Adv · 2020-01-01

基于全球II期JULIET研究,分析了111例接受tisagenlecleucel治疗的复发/难治性DLBCL患者的细胞动力学与临床/产品参数的关系。结果显示细胞动力学与产品特征、内在/外在因素、剂量或免疫原性无关;扩增与缓解持续时间可能相关但未达统计学显著性,且扩增与细胞因子释放综合征严重程度及托珠单抗使用相关。

要点

  • 缓解者中tisagenlecleucel持久性通过流式检测最长554天,qPCR最长693天。
  • 扩增(Cmax)与缓解持续时间可能相关但未达统计学显著性(HR 0.79,95%CI 0.61-1.01)。
  • 扩增与CRS严重程度及托珠单抗使用相关,与神经系统事件无关。

核心结论

  • Tisagenlecleucel在成人复发/难治性DLBCL中的细胞动力学特征增进了对体内扩增及其与安全性/有效性终点关系的理解。

研究设计与样本

  • 全球II期JULIET研究,纳入111例接受tisagenlecleucel治疗的成人复发/难治性DLBCL患者,分析细胞动力学与临床/产品参数的相关性。

主要发现

  • 缓解者中tisagenlecleucel持久性通过流式检测最长554天,通过qPCR最长693天;非缓解者分别为最长400天和374天。
  • 未发现细胞动力学(qPCR)与产品特征、内在/外在因素、剂量或免疫原性之间的关系。
  • 多数3个月缓解者在该时点可检测到转基因,并持续存在≥6个月。
  • 扩增(Cmax)与缓解持续时间可能相关但未达统计学显著性(HR 0.79,95%CI 0.61-1.01)。
  • 扩增与CRS严重程度及托珠单抗使用相关,与神经系统事件无关;转基因水平与B细胞水平相关。

关键数值与推荐

  • 剂量与CRS严重程度相关,但调整基线肿瘤负荷后未达统计学显著性。
  • DLBCL中无论缓解与否暴露量相似,且扩增低于B-ALL,可能与肿瘤位置和/或T细胞内在因素差异有关。
  • DLBCL与B-ALL在扩增与CRS严重程度的关系及剂量与暴露无关方面表现相似。

临床怎么用

  • 临床可关注tisagenlecleucel扩增水平与CRS严重程度及托珠单抗使用的关联,用于安全性监测。
  • 剂量与暴露无关,调整基线肿瘤负荷后剂量与CRS严重程度无关,支持按固定剂量给药。

局限性

  • 扩增与缓解持续时间的关联未达统计学显著性,需进一步研究确认。
  • DLBCL与B-ALL扩增差异的原因可能涉及肿瘤位置和/或T细胞内在因素,但未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was demonstrated for 554 and 400 days maximum by flow cytometry and for 693 and 374 days maximum by quantitative polymerase chain reaction (qPCR). No relationships were identified between cellular kinetics (qPCR) and product characteristics, intrinsic/extrinsic factors, dose, or immunogenicity. Most patients with 3-month response had detectable transgene at time of response and continued persistence for ≥6 months. Expansion (maximal expansion of transgene/CAR-positive T-cell levels in vivo postinfusion [Cmax]) was potentially associated with response duration but this did not reach statistical significance (hazard ratio for a twofold increase in Cmax, 0.79; 95% confidence interval, 0.61-1.01). Tisagenlecleucel expansion was associated with cytokine-release syndrome (CRS) severity and tocilizumab use; no relationships were observed with neurologic events. Transgene levels were associated with B-cell levels. Dose was associated with CRS severity, but this was not statistically significant after adjusting for baseline tumor burden. In contrast to the results from B-cell precursor acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia, similar exposure was observed in DLBCL in this study regardless of response and expansion was lower in DLBCL than B-ALL, likely from differences in cancer location and/or T-cell intrinsic factors. Relationships between expansion and CRS severity, and lack of relationships between dose and exposure, were similar between DLBCL and B-ALL. Tisagenlecleucel cellular kinetics in adult relapsed/refractory DLBCL improve current understanding of in vivo expansion and its relationships with safety/efficacy endpoints. This trial was registered at www.clinicaltrials.gov as #NCT02445248.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Awasthi R, Pacaud L, Waldron E, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020. PMID: 32045475. doi:10.1182/bloodadvances.2019000525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。